<DOC>
	<DOCNO>NCT02658214</DOCNO>
	<brief_summary>Durvalumab Tremelimumab combination first-line chemotherapy follow indication : Ovarian/peritoneal/fallopian tube cancer , SCCHN , TNBC , SCLC gastric/GEJ cancer .</brief_summary>
	<brief_title>Durvalumab Tremelimumab Combination With First-Line Chemotherapy Advanced Solid Tumors</brief_title>
	<detailed_description>The study screen approximately 100 patient order total approximately 80 evaluable patient 5 cohort first-line chemotherapy regimen combine durvalumab + tremelimumab . This study evaluate safety tolerability durvalumab ( MEDI4736 ) + tremelimumab combination first line chemotherapy regimens patient locally advance metastatic solid tumor : ovarian/peritoneal/fallopian tube cancer , squamous cell carcinoma head neck ( SCCHN ) , triple negative breast cancer ( TNBC ) , small cell lung carcinoma ( SCLC ) , gastric/gastro-esophageal junction ( GEJ ) cancer .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>1 . Age ≥18 year time screen 2 . Written inform consent locally require authorization 4 . Patients histologically cytologically document chemotherapynaive locally advanced unresectable metastatic ovarian/peritoneal/fallopian tube cancer , SCCHN , TNBC , SCLC , gastric cancer/GEJ . 4a . SCCHN patient candidate definitive chemoradiation eligible participate . 4b . Gastric/GEJ cancer define HER2 negative adenocarcinoma ( eligible antiHER2 therapy ) . 5 . ECOG performance status 0 1 6 . At least 1 lesion , previously irradiate , accurately measure baseline 7 . No prior exposure immunemediated therapy 8 . Adequate organ marrow function 1 . Receipt investigational anticancer therapy within 28 day 5 halflives , whichever longer , prior first dose study treatment 2 . Brain metastasis spinal cord compression unless asymptomatic treat stable steroid anticonvulsant least 1 month prior study treatment 3 . Any unresolved Grade ≥2 toxicity previous anticancer therapy 4 . Active prior document autoimmune inflammatory disorder 5 . Uncontrolled intercurrent illness , include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , cardiac arrhythmia , interstitial lung disease , psychiatric illness/social situation would limit compliance study requirement , substantially increase risk incur AEs study drug , compromise ability patient give write informed consent 6 . Mean QT interval correct heart rate use Fridericia 's formula ( QTcF ) ≥470 m 20 . Active tuberculosis 7 . Active infection include hepatitis B , hepatitis C , human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>durvalumab , MEDI4736 , tremelimumab , small-cell lung , head neck , triple negative breast , gastric/GEJ ovarian cancer , immuno oncology , first-line chemo</keyword>
</DOC>